These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38306166)

  • 1. Zuranolone: A Breakthrough in the Treatment of Postpartum Depression.
    Diaz ZM; Adashi EY
    J Womens Health (Larchmt); 2024 Apr; 33(4):407-408. PubMed ID: 38306166
    [No Abstract]   [Full Text] [Related]  

  • 2. Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression.
    Hitt EM
    Clin Ther; 2024 May; 46(5):433-438. PubMed ID: 38697873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon.
    Nashwan AJ; Rehan ST; Imran L; Abbas SG; Khan SF
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jun; 132():110983. PubMed ID: 38412941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis.
    Winslow M; White E; Rose SJ; Salzer E; Nemec EC
    Int J Clin Pharm; 2024 Jun; 46(3):590-601. PubMed ID: 38489051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression.
    Carlini SV; Osborne LM; Deligiannidis KM
    Dialogues Clin Neurosci; 2023 Dec; 25(1):92-100. PubMed ID: 37796239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Oral Treatment Specific for Postpartum Depression.
    Blakely KK
    Nurs Womens Health; 2024 Aug; 28(4):315-318. PubMed ID: 38768648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.
    Barnes KN; Vogl CM; Nelson LA
    Ann Pharmacother; 2024 Jul; 58(7):728-734. PubMed ID: 37876133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redefining Postpartum Depression Treatment: The Clinical Potential of Zuranolone.
    Nashwan AJ; Rehan ST; Imran L; Abbas SG; Khan S
    Asian J Psychiatr; 2024 Jan; 91():103849. PubMed ID: 38056137
    [No Abstract]   [Full Text] [Related]  

  • 9. Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care.
    Jarman AF; MacLean JV; Barron RJ; Wightman RS; McGregor AJ
    Clin Ther; 2020 Jan; 42(1):231-235. PubMed ID: 31910998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on approved and emerging drugs for the treatment of postpartum depression.
    Çulcu EA; Demiryürek Ş; Demiryürek AT
    Ideggyogy Sz; 2024 Jul; 77(7-8):227-235. PubMed ID: 39082257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. US Food and Drug Administration approval of esketamine and brexanolone.
    Cristea IA; Naudet F
    Lancet Psychiatry; 2019 Dec; 6(12):975-977. PubMed ID: 31680013
    [No Abstract]   [Full Text] [Related]  

  • 12. Zuranolone: First Approval.
    Heo YA
    Drugs; 2023 Nov; 83(16):1559-1567. PubMed ID: 37882942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
    Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA
    Sharma R; Bansal P; Saini L; Sharma N; Dhingra R
    Pharmacol Biochem Behav; 2024 May; 238():173734. PubMed ID: 38387651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment on "The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis".
    Kotake K
    Int J Clin Pharm; 2024 Aug; 46(4):998. PubMed ID: 38896391
    [No Abstract]   [Full Text] [Related]  

  • 16. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression.
    Powell JG; Garland S; Preston K; Piszczatoski C
    Ann Pharmacother; 2020 Feb; 54(2):157-163. PubMed ID: 31476884
    [No Abstract]   [Full Text] [Related]  

  • 17. Postpartum Depression: Identification and Treatment in the Clinic Setting.
    Kroska EB; Stowe ZN
    Obstet Gynecol Clin North Am; 2020 Sep; 47(3):409-419. PubMed ID: 32762926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroactive steroids - new possibilities in the treatment of postpartum depression.
    Žigová L; Massarová P; Vranecová K; Hrubá O; Adamičková A; Gažová A
    Ceska Slov Farm; 2022; 71(4):142-150. PubMed ID: 36208918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States.
    O'Callaghan L; Chertavian E; Johnson SJ; Ferries E; Deligiannidis KM
    J Med Econ; 2024; 27(1):492-505. PubMed ID: 38465615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brexanolone for postpartum depression.
    Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF
    Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.